Nephrocare Health Services
NEPHROPLUSNSE

Nephrocare Health Services

₹598.70-6.40 (1.06%)1D
1D
1W
1M
3M
6M
1Y
3Y
5Y
All
Create Stock SIPAutomate your investments in this
Overview
Technicals
News
Events

Performance

Today’s low
596.00
Today’s high
615.55
52 week low
446.00
52 week high
663.90
Open price
605.05
Previous close
605.10
Live volume
1,50,243
Lower circuit
484.10
Upper circuit
726.10

Fundamentals

Market Cap
₹6,081Cr
ROE
6.88%
P/E Ratio(TTM)
79.11
EPS(TTM)
7.66
P/B Ratio
5.45
Dividend Yield
0.00%
Industry P/E
59.72
Book Value
111.27
Debt to Equity
0.07
Face Value
2

Financial performance

Quarterly
Yearly
All Financials
MAR '26
Revenue (Cr)
₹277
+5.38%
Profit (Cr)
₹30.37
-5.80%
-75093.75187.5281.3
Dec '24
Mar '25
Sep '25
Dec '25
Mar '26
Revenue growthValue
1Y (TTM)+37%
3Y CAGR+33%
Profit growthValue
1Y (TTM)+51%
3Y CAGR+73%

About

Nephrocare Health Services Limited operates a chain of dialysis centers and provides comprehensive renal care services.;
CEO/MD
Dr. Pratim Sengupta
Founded in
2014
NSE symbol
NEPHROPLUS

Shareholding Pattern

Jul '25
Dec '25
Mar '26
Promoters
63.85%
Foreign Institutions
20.89%
Retail And Others
6.61%
Other Domestic Institutions
5.47%
Mutual Funds
3.17%

Mutual Funds Invested (4)

Livesquawk
Nephrocare Health Services to invest up to ₹100M in its Nepal operations. The investment aims to support expansion and operations in Nepal.
Livesquawk
Nephrocare Health Q4 EBITDA rises to ₹537M from ₹513M YoY. EBITDA margin declines to 20.2% from 23.4% YoY.
Livesquawk
Nomura initiates Buy on Nephrocare India, target price Rs 605, citing sticky dialysis services and recurring revenue. NephroPlus's strong market position and 18.3% EBITDA CAGR from mid-to-high-teen revenue growth drive optimism.
2026
19
May
Quarterly & Annual Result
Release date
10
Feb
Quarterly Result
Release date
Events calendar
View upcoming events in other stocks